Alcohol and HIV Decrease Proteasome and Immunoproteasome Function in Macrophages: Implications for Impaired Immune Function During Disease by Haorah, James et al.
University of Nebraska - Lincoln 
DigitalCommons@University of Nebraska - Lincoln 
Public Health Resources Public Health Resources 
2004 
Alcohol and HIV Decrease Proteasome and Immunoproteasome 
Function in Macrophages: Implications for Impaired Immune 
Function During Disease 
James Haorah 
Liver Study Unit, The Center for Neurovirology and Neurodegenerative Disorders, University of Nebraska 
Medical Center, Omaha, NE 68198-5215, USA 
David Heilman 
Liver Study Unit, The Center for Neurovirology and Neurodegenerative Disorders, University of Nebraska 
Medical Center, Omaha, NE 68198-5215, USA 
Casey Diekmann 
Liver Study Unit, The Center for Neurovirology and Neurodegenerative Disorders, University of Nebraska 
Medical Center, Omaha, NE 68198-5215, USA 
Natalia Osna 
The Veterans Affairs Medical Center, Omaha, NE USA 
Terrence M. Donohue Jr. 
The Veterans Affairs Medical Center, Omaha, NE USA 
See next page for additional authors Follow this and additional works at: https://digitalcommons.unl.edu/publichealthresources 
 Part of the Public Health Commons 
Haorah, James; Heilman, David; Diekmann, Casey; Osna, Natalia; Donohue Jr., Terrence M.; Ghorpade, 
Anuja; and Persidsky, Yuri, "Alcohol and HIV Decrease Proteasome and Immunoproteasome Function in 
Macrophages: Implications for Impaired Immune Function During Disease" (2004). Public Health 
Resources. 57. 
https://digitalcommons.unl.edu/publichealthresources/57 
This Article is brought to you for free and open access by the Public Health Resources at 
DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Public Health Resources by 
an authorized administrator of DigitalCommons@University of Nebraska - Lincoln. 
Authors 
James Haorah, David Heilman, Casey Diekmann, Natalia Osna, Terrence M. Donohue Jr., Anuja Ghorpade, 
and Yuri Persidsky 
This article is available at DigitalCommons@University of Nebraska - Lincoln: https://digitalcommons.unl.edu/
publichealthresources/57 
Alcohol and HIV decrease proteasome and immunoproteasome
function in macrophages: implications for impaired
immune function during disease
James Haoraha,b, David Heilmana,b, Casey Diekmanna,b, Natalia Osnac,
Terrence M. Donohue Jr.c, Anuja Ghorpadea,b, Yuri Persidskya,b,*
a Liver Study Unit, The Center for Neurovirology and Neurodegenerative Disorders, University of Nebraska Medical Center,
Omaha, NE 68198-5215, USA
b Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE 68198-5215, USA
c The Veterans Affairs Medical Center, Omaha, NE USA
Received 9 March 2004; accepted 12 July 2004
Abstract
Proteasomes (proteinase complexes, PR) and immunoproteasomes (IPR) degrade damaged proteins and affect protein processing
required for antigen presentation by mononuclear phagocytes. These critical immune processes are attenuated during progressive
HIV-1 infection and are affected by alcohol abuse. To investigate the mechanisms underlying these functional changes, we measured
PR and CYP2E1 activities [an ethanol (EtOH) metabolizing enzyme] and reactive oxygen species (ROS) in human monocyte-de-
rived macrophages (MDM) following HIV-1 infection and EtOH treatment. We observed progressive declines of PR activity
and PR/IPR contents in HIV-1-infected MDM. PR activity and IPR expression increased after IFN-c stimulation but reduced after
HIV-1 infection. EtOH inhibited both IFN-c-induced PR and IPR. Paradoxically, EtOH attenuated PR catalytic activity in infected
MDM and suppressed viral replication. Elevated ROS followed EtOH exposure and paralleled decreased PR activity. The latter was
restored by anti-oxidant. The data support the notion that HIV-1 infection and EtOH may work in concert to affect immune func-
tion including antigen presentation and thereby affect disease progression.
 2004 Elsevier Inc. All rights reserved.
Keywords: Mononuclear phagocytes; CYP2E1; Reactive oxygen species; Antigen presentation
1. Introduction
Alcohol abuse can affect the progression of HIV-1 dis-
ease [1,2]. Acute and chronic alcohol abuse impairs a
broad range of immune functions and thus is implicated
as a cofactor in HIV-1 infection. Nonetheless, the mech-
anisms by which alcohol affects the HIV-1 cellular targets
are unknown. Ethanol (EtOH) exposure leads to dimin-
ished T- and B-lymphocyte numbers, immunoglobulin
and pro-inflammatory cytokine [tumor necrosis factor
(TNF)-a, interleukin (IL)-1b, and IL-6] production
[3–6]. EtOH can also affect antigen presentation by mac-
rophages and dendritic cells [7], phagocytosis [8] and
intracellular killing [9]. Macrophage activation induced
by lipopolysaccharide is attenuated after EtOH adminis-
tration [10]. EtOH induces secretion of anti-inflammatory
factors (transforming growth factor b and prostaglandin
E2) [1,11,12]. Acute EtOH intoxication can also suppress
inflammatory responses in normal subjects through inhi-
bition of accessory function and leukocyte migration
[10,13–15]. In simian immunodeficiency virus (SIV)-in-
fected animals EtOH suppresses TNF-a and leads to in-
creased susceptibility to secondary infections [16].
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Degradation of damaged or short-lived regulatory
proteins is a function of the proteasome (PR). The PR
consists of a 20S catalytic core that is activated by bind-
ing of the PA28 regulator [17–19]. PR constitutive
subunits (X, Y, Z) possess chymotrypsin-like (X), tryp-
sin-like (Y), and peptidyl-glutamyl-peptide hydrolase
(Z) activities [20,21]. PR activity is up-regulated by
pro-inflammatory cytokines [interferon (IFN)-c TNF-a
and IL-6] [20,22]. After IFN-c stimulation, constitutive
PR subunits X, Y, and Z are replaced by inducible PR
subunits LMP2, LMP7, and MELC-1 [20,21]. Process-
ing of protein antigens within inducible subunits of
IPR is important in subsequent conjugation with the
class I major histocompatibility complex (MHC) re-
quired for antigen presentation [21,23]. While no data
are available to suggest that alcohol affects PR function
in antigen presenting cells (APC), studies performed
using liver cells point to PR impairment as a result of
exposure to EtOH or its metabolites [24].
Microsomal enzymes belonging to the cytochrome
P450 family catalyze a variety of hydroxylation reac-
tions. Cytochrome P450 2E1 (CYP2E1) is a terminal
oxidase in the microsomal respiratory chain and is in-
volved in EtOH metabolism [25]. Monocyte-derived
macrophages (MDM) and rat liver macrophages express
CYP2E1 [26,27]. CYP2E1 plays a central role in EtOH
metabolism by macrophages [28]. Inhibition of
CYP2E1, attenuated EtOH-induced reduction of PR
activities in vivo, in liver cells [29,30]. Such effects are as-
sumed to be associated with increased production of
reactive oxygen species (ROS). We now hypothesize that
EtOH may affect PR function and in doing so affect
antigen presentation. We demonstrate that both HIV-1
infection and EtOH diminish PR activity and IPR con-
tents in macrophages and thus, may contribute to im-
mune dysfunction in an infected human host.
2. Materials and methods
2.1. Isolation and virus infection of human monocyte-
derived macrophages
Human monocytes were isolated from HIV-1, 2, and
hepatitis B seronegative donors and purified by counter-
current centrifugal elutriation [31]. Monocytes were cul-
tured at 30 · 106cells/T75 flask in 10ml in Dulbeccos
modified Eagles medium (Sigma Chemical, St. Louis,
MO) with 10% heat inactivated human serum, 1%
glutamine, 50lg/ml gentamicin (Sigma), 10lg/ml cipro-
floxacin (Sigma), and 1000U/ml human macrophage
colony-stimulating factor (a generous gift from Genetics
Institute, Cambridge, MA). In parallel, monocytes were
cultured in 96-well plates for viability assays at 105cells/
well in 100ll media for seven days, changing the med-
ium every third day. MDM then were infected with
cell-free macrophage-tropic strain HIV-1ADA inoculum
(4 · 105cpm/106cells) standardized for all experiments
by reverse transcriptase (RT) activity [32]. RT activity
was determined in triplicate in culture fluids after addi-
tion of 0.05% Nonidet P-40 (Sigma), 10lg/ml poly(A),
0.25lg/ml oligo(dt) (Pharmacia Fine Chemicals, Piscat-
away, NJ), and 5mM dithiothreitol thymidine 5 0-tri-
phosphate (2Ci/mmol; Amersham, Arlington Heights,
IL) in Tris–HCl buffer (pH 7.9) for 24h at 37 C. Radi-
olabeled nucleic acids were precipitated with cold 10%
trichloroacetic acid (TCA) and 95% EtOH in an auto-
matic cell harvester (Packard Instrument Company,
Meriden, CT) on paper filters. Radioactivity was esti-
mated by liquid scintillation spectroscopy. Level of
infection was also assessed in MDM (3, 5, and 9 days
after infection) by staining for HIV-1 p24 [using primary
monoclonal antibodies (Abs) from Dako, Carpenteria,
CA, detected by avidin–biotin immunoperoxidase, Vec-
tastain Elite ABC kit, Vector Laboratories, Burlingame,
CA]. Immunostained cells were analyzed with a Nikon
Microphot-FXA microscope. RT results were normal-
ized to viable cell numbers determined by 3-[4,5-dimeth-
ylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT)
assay [33]. Briefly, after collecting the culture media
from HIV-1 infected MDM in 96-well plate for RT, cells
were incubated with MTT (5mg/ml solution of 10%
FBS in PBS) for 45min at 37 C. Reduction of MTT
to formazan was assessed at 490nm using plate reader.
2.2. Cell treatments
After treating MDMwith 25mM EtOH, ethanol con-
centration in culture fluidswas determined byusingEtOH
assay kit (Diagnostic Chemicals Limited, P.E.I. Canada).
This was done to assay possible evaporation of EtOH
after 8, 24, and 48h incubation at 37 C. EtOH recovery
was 95–98% when compared to the start concentration.
MDM were stimulated with IFN-c (10ng/ml, R&D Sys-
tems, Minneapolis, MN) in order to mimic immune acti-
vation in HIV-1 infected cells and to induce IPR.
2.3. Protein extraction
After 48h treatment period, media was aspirated
from T75 culture flasks, followed by two successive
washes with ice-cold 20mM phosphate buffered saline.
Cells were scraped into 1ml ice-cold extraction buffer
(50mM Tris–HCl, pH 7.5, containing 20% glycerol,
5mM ATP, 5mMMgCl2, and 0.5mM DTT). After son-
icating the cell suspension on ice, a 300ll lysate aliquot
was stored from each sample without the protease inhib-
itor for the analysis of PR chymotrypsin-like activity
and for the immunoblots of PR and IPR. Before sub-
jecting to denaturing electrophoresis under non-reduc-
ing conditions, lysates were centrifuged at 14,000rpm
(15,000g) for 15min at 4 C. Lysates then were
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centrifuged at 35,000rpm (105,000g) for 1h at 4 C to
sediment the microsome fraction for CYP2E1 assay.
2.4. PR Chymotrypsin-like activity
Chymotrypsin-like activity was assayed using 7-ami-
no-4-methylcoumarin as the standard and N-succi-
nyl-LEU-LEU-VAL-TYR-7-amino-4-methylcoumarin
(LLVY assay) as the fluorogenic peptide substrate (Sig-
ma). Chymotrypsin-like activity was assayed in 96-well
plates containing 40lM LLVY substrate and 20ll sam-
ple lysate in a reaction mixture of 50ll in 0.2M Tris–
HCl, pH 7.4, either in the presence or absence of
0.03% sodium dodecyl sulfate (SDS). Experimental sam-
ples and appropriate controls were set up in triplicate
and incubated for 1h at 37 C. The reaction was stopped
by adding 190ll of 0.1M Tris–HCl, pH 9.1, and 60ll of
1% SDS to each well. The fluorescence was measured at
390nm excitation and 440nm emission.
2.5. CYP2E1 activity
CYP2E1 activity was determined by the hydroxyl-
ation of p-nitrophenol to 4-nitrocatechol catalyzed by
CYP2E1 following an established method [27]. Reaction
mixtures of 50ll containing 2mM b-nicotinamide ade-
nine dinucleotide phosphate and 0.8mM p-nitrophenol
(both from Sigma) were added to 1.5ml microcentrifuge
tubes containing 50ll of microsomal suspension in trip-
licate on ice. Blank tubes of identical composition were
prepared except that 20% TCA was added prior to the
reaction mixture on ice. The reactions were terminated
by adding 30ll of 20% TCA immediately after 1h incu-
bation at 37 C in a water bath shaker. After 15min, the
sample and blank tubes were centrifuged for 10min at
14,000rpm to remove insoluble proteins. Supernatants
were transferred to 96-well plate and 10 ll of 10N
NaOH were added for color development. The absor-
bance was read at 540nm in the 96-well Vmax kinetic
reader (Molecular Devices). CYP2E1 activity from
MDM microsome was calculated using 4-nitrocatechol
(Sigma) as the internal standard. CYP2E1 activity was
expressed as nmol/mg protein.
2.6. Western blot analyses
Western blotting was performed as previously de-
scribed [34]. Briefly, 10lg lysate protein was loaded onto
1.5mm thick 4–15% gradient polyacrylamide precast gels
(Bio-Rad, Hercules, CA) those were electrophoresed un-
der denatured non-reducing conditions. Proteins from
the gels were transblotted onto nitrocellulose membranes
(0.45lm pore size) at 60V for 1h at 24 C. The mem-
branes were blocked with superblock (Bio-Rad) contain-
ing 2% nonfat dry milk for 40min at 24 C. Blots were
incubated for 1h at 24 C with the respective primary
antibody in superblock solution that was 10-fold diluted
with 20mM phosphate buffer saline, pH 7.4, containing
0.1% Tween 20 (PBST), followed by three successive
washes with PBST for 5min. Immunoreactive bands
were detected by luminol detection kit (Pierce, Rockford,
IL) followed by exposure to Kodak X-ray film. The
bands were quantified densitometrically as arbitrary vol-
ume integration units using the Molecular Dynamics
ImageQuant software (Sunnyvale, CA). Results were ex-
pressed as the ratio of the density of the target protein
immunoreactivity to that of the internal standard a-actin
immunoreactivity (which was not affected by EtOH
treatment, HIV-1 infection or IFN-c). The following
Abs were used for Western blot: polyclonal Abs to 20S
and 19S, monoclonal Abs to LMP2 or LMP7 (all from
Affinity Research Products, Mamhead, UK), polyclonal
Abs to CYP2E1 (Research Diagnostic, Flander, NJ),
and monoclonal Abs to 3-nitrotyrosine (Upstate Cell
Signaling Solutions, Lake Placid, NY).
2.7. ROS detection by the dichlorofluorescein diacetate
assay
Dichlorofluorescein diacetate (DCF-DA) (an indica-
tor for ROS) is non-fluorescent until the acetate groups
are removed by intracellular esterases and then oxidation
occurswithin the cell [35].DCF-DA is converted to highly
fluorescentDCFby cellular peroxides. The fluorescence is
detected at excitation 488nm and at emission 525nm
using a fluorescence plate reader. Sample mixtures con-
tained 10ll of cell lysate, 50ll of DCF-DA (Molecular
Probes, Eugene, OR) and 140ll of distilled water and
incubated at 37 C for 15min followed by the detection
of fluorescence. The blank mixtures contained 50ll of
methanol instead of 50ll of DCF-DA. The intensity val-
ues of the blanks were subtracted from the experimental
sample intensity values. The results were expressed as spe-
cific mean fluorescence intensity per mg protein.
2.8. Statistical analyses
The significance of the effects of HIV-1, EtOH, and
IFN-c on PR activity, CYP2E1 activity, ROS produc-
tion, and expression of PR/IPR, CYP2E1 and 3-nitroty-
rosine were assessed using two-way ANOVA with
Newman–Keuls post-test for multiple comparisons. A
p value of < 0.05 was considered significant.
3. Results
3.1. HIV-1 infection decreases PR activity and PR/IPR
content in MDM
We first investigated the effect of MDM differentia-
tion on the PR chymotrypsin-like activity. This increased
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13-fold from day one after monocyte isolation
(1.13 ± 0.17nmol/mg protein) through day nine
(14.82 ± 0.19nmol/mg protein), followed by a plateau
phase (data not shown). HIV-1 infection of MDM re-
sulted in 8–43% decline in the chymotrypsin-like activity
3–9 days after infection (Fig. 1A), while the normalized
RT activity increased 6.5 times from days 3 to 9 post-in-
fection (1509, 7593, and 9800cpm RT activity, respec-
tively, for days 3, 5, and 9 post-infection). A negative
correlation was observed between level of RT activity
and PR activity (correlation coefficient; r = 0.804,
p < 0.01) in HIV-1-infected MDM. The percentage of in-
fected MDM at days 3, 5, and 9 were 3, 38, and 85%,
respectively, as determined by HIV-1 p24 immunostain-
ing. A modest decrease in cell viability of HIV-1 infected
MDM (17–20%) was detected at 3–9 days post-infection
when compared to uninfected cells. The decline in PR
activity was not due to cell death by HIV-1 infection, be-
cause each sample was extracted only from viable adher-
ent MDM and all assays were performed in samples
adjusted by protein content. Treatment of lysates from
uninfected MDM with the 20S PR activator 0.03%
SDS [36], resulted in 4-fold increase of activity indicating
high levels of 20S PR. HIV-1-infected MDM demon-
strated only 2-fold increase in PR activity in the presence
of SDS, pointing to the impaired function of 20S by
HIV-1 infection in MDM (data not shown).
These functional changes paralleled expression of PR
subunits detected by Western blot assays. HIV-1-infect-
ed MDM showed a 20% (20S) and 26% (19S) decrease
when compared with uninfected cells (p < 0.001) (Fig.
1B). Expression of LMP2 and LMP7 subunits of IPR
diminished by 30 and 24% (p < 0.001), respectively
(Fig. 1B), indicating that viral infection negatively af-
fected IPR content in MDM. These results indicate a
specific effect of HIV-1 infection on PR function/expres-
sion in MDM. These may not be attributed to HIV-in-
duced changes in cell viability, because equal amount
of protein was loaded from each sample for immuno-
blots and results were further normalized to internal
standard (a-actin). Thus, decreased of PR/IPR activity
and expression in HIV-1 infected MDM are related to
the levels of HIV-1 infection and replication.
3.2. Effects of IFN-c on PR activity and PR/IPR content
in MDM
To mimic immune activation in HIV-1 infected cells,
replicate infected or uninfected MDM were stimulated
with IFN-c (10ng/ml). IFN-c up-regulated chymotryp-
sin-like activity in MDM (199%, p < 0.001) and HIV-1
MDM (218%, p < 0.001) (Fig. 2A). Despite IFN-c treat-
ment PR activity was 60% lower in infected as compared
to uninfected IFN-c stimulated MDM. IFN-c treatment
had no effect on cell viability (data not shown), IFN-c
treatment did not alter the levels of 20S or 19S PR in
both infected and uninfected MDM when compared to
unstimulated cells (Fig. 2B). Contrary to the findings
for constitutive PR, the levels of LMP2 and LMP7
(Fig. 2C) in IFN-c-treated MDM were elevated by 29
and 27% when compared to non-treated cells
(p < 0.001). Similarly, IFN-c treatment increased levels
of LMP2 and LMP7 by 28 and 17% in HIV-1-infected
MDM (p < 0.001). In agreement with catalytic activity,
expression of IPR was lower in virus-infected and
IFN-c-treated MDM (LMP2, 46% and LMP7, 43%,
p < 0.001) when compared to IFN-c-treated uninfected
MDM. These results suggest that a major increase in
PR activity seen after IFN-c stimulation is associated
with IPR but not constitutive PR subunits.
Fig. 1. Effects of HIV-1 infection on chymotrypsin-like activity and
proteasome content in MDM. (A) Chymotrypsin-like activity was
measured in HIV-1-infected MDM at days 3, 5, and 9 post-infection.
We used 7-amino-4-methylcoumarin as an internal standard and N-
succinyl-LEU-LEU-VAL-TYR-7-amino-4-methylcoumarin (LLVY)
as a fluorogenic peptide substrate for the PR activity assay. Fluores-
cence was measured at 390nm (excitation) and 440nm (emission).
LLVY activity was expressed in nmol/mg protein. (B) Content of 20S
constitutive PR, 19S regulatory (ATPase dependent) subunit of 26S
PR, LMP2, and LMP7 subunits of IPR were measured in uninfected
or infected MDM at day 9 post-infection. Results were expressed as
the ratio of target protein immunoreactivity to that of internal
standard a-actin. Values obtained from HIV-1 uninfected MDM were
used as controls (normalized to a value of 100%). Each bar was derived
from mean value of four replicates ± SEM. Data were statistically
analyzed using two-way ANOVA with Newman–Keuls post-test.
Representative data from four experiments performed with indepen-
dent MDM donors are shown.
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3.3. Effects of EtOH on PR activity and PR/IPR content
in MDM
MDM were treated with 25mM EtOH. The concen-
tration used was based on our initial experiments, which
demonstrated that MDM viability or PR activity was
not changed after 48h treatment with 0.25–25mM
EtOH (data not shown). Cell viability was adversely af-
fected by EtOH concentrations higher than 25mM (data
not shown). Although addition of 25mM EtOH did not
change chymotrypsin-like activity in uninfected MDM
(Fig. 3), it decreased PR activity (by 25%, p < 0.001)
up-regulated by IFN-c to the levels seen in unstimulated
cells (Fig. 3). Similar to the functional changes, EtOH
decreased the levels of IFN-c-induced IPR, LMP2,
and LMP7 by 22% in EtOH/IFN-c-treated MDM as
compared to IFN-c stimulated MDM (p < 0.001, Figs.
4A and B), while expression of 20S and 19S was not al-
tered by EtOH treatment in uninfected cells (Figs. 4C
and D). Exposure of infected MDM to EtOH prevented
decrease of chymotrypsin-like activity by 7% (p < 0.05,
day 3, data not shown), 18% (p < 0.02, day 5, data not
shown), and 31% (p < 0.001, day 9 post-infection, Fig.
3, bars 3 and 7). Opposite to results seen in uninfected
cells, chymotrypsin-like activity in IFN-c-stimulated
HIV-1-infected MDM with EtOH treatment was moder-
ately higher (10%) as compared to IFN-c stimulated
HIV-1-infected MDM without EtOH exposure
(p < 0.01; Fig. 3, bars 4 and 8). The contents of both
constitutive PR and IPR were not changed after EtOH
treatment of infected MDM as compared to untreated
cells without IFN-c stimulation (Figs. 4A–D).
To establish whether EtOH had dose-dependent ef-
fects on PR activity, infected MDM were treated with
varied concentrations of EtOH (0.25, 2.5, and 25mM)
for 8, 24, 48, and 72h. All concentrations of EtOH
had a protective effect on chymotrypsin-like activity in
infected cells (Fig. 5). Treatment with EtOH (0.25–
25mM) for 48h decreased RT activity by 26–33%
(p < 0.01) (Fig. 5). These effects on PR activity were
Fig. 2. Effects of IFN-c on proteasome activity and level of expression
in MDM. (A) Changes in the proteasomal catalytic activity in MDM
(day 9 post-infection) after 48h stimulation with IFN-c. (B) Content of
20S constitutive PR, 19S regulatory (ATPase dependent) subunit of
26S PR, and (C) LMP2 and LMP7 subunits of IPR were measured in
uninfected or infected MDM at day 9 post-infection treated for 48h
with IFN-c. Results were expressed as the ratio of target protein
immunoreactivity to that of internal standard a-actin. Values obtained
from HIV-1 uninfected and IFN-c untreated MDM were used as a
controls (normalized to a value of 100%). Each bar was derived from
mean value of four replicates ± SEM. Data were statistically analyzed
using two-way ANOVA with Newman–Keuls post-test. Representa-
tive data from four experiments performed with independent MDM
donors are shown.
Fig. 3. Effects of EtOH on chymotrypsin-like activity in MDM.
Changes in the proteasomal catalytic activity in MDM at day 9 post-
infection after 48h stimulationwith IFN-cwith orwithout simultaneous
EtOH treatment. Values represent the mean of four determina-
tions ± SEM. Data were statistically analyzed using two-way ANOVA
with Newman–Keuls post-test. Representative data from four experi-
ments performed with independent MDM donors are shown.
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inversely proportional to the levels of HIV-1 replication.
Uninfected cells treated with 25mM EtOH and/or INF-
c served as positive controls (data not shown). As ex-
pected, treatment of uninfected MDM with EtOH did
not change PR activity, and INF-c treatment up-regu-
lated PR activity.
Fig. 4. Effects of EtOH on proteasome expression in MDM. Changes in the proteasome expression in MDM (day 9 post-infection) after 48h
stimulation with IFN-c with or without simultaneous EtOH treatment. Results were expressed as the ratio of target protein immunoreactivity to that
of internal standard, actin. Values obtained from HIV-1 uninfected and IFN-c untreated MDM were used as a controls (normalized to a value of
100%). (A) Ratio of LMP2/actin, (B) LMP7/actin, (C) 20S/actin, and (D) 19S/actin. Each bar was derived from mean value of four
replicates ± SEM. Data were statistically analyzed using two-way ANOVA with Newman–Keuls post-test. Representative data from four
experiments performed with independent MDM donors are shown.
Fig. 5. Effects of EtOH concentrations on chymotrypsin-like activity and virus replication in HIV-1-infected MDM. Changes in PR and RT
activities in HIV-1 infected MDM at day 9 post-infection after 8, 24 or 48h treatment without or with different EtOH concentrations. Results
obtained from HIV-1 infected MDMwithout EtOH treatment are indicated by ‘‘EtOH’’ and with EtOH treatment indicated by ‘‘+EtOH.’’ The bar
graphs represent the PR activity (left Y axis) and the line graphs above the bars show the RT activity (right Y axis). Values are the mean of four
determinations ± SEM. Data were statistically analyzed using two-way ANOVA with Newman–Keuls post-test. Representative data from four
experiments performed with independent MDM donors are shown.
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In summary, EtOH inhibited both INF-c-induced
IPR activity and increased IPR expression in uninfected
MDM. EtOH decreased HIV-1 replication in infected
MDM and ameliorated virus-induced decrease in PR
activity. Inhibiting effects of EtOH on HIV-1 replication
and IFN-c-induced PR activity led to slight increase in
PR activity in EtOH treated/IFN-c stimulated infected
MDM.
3.4. EtOH metabolism by CYP2E1 leads to ROS
production in MDM
CYP2E1 is suggested to be a major pathway for
EtOH metabolism in MDM [37]. To further confirm this
finding, we studied CYP2E1 enzyme activity in MDM.
While modest CYP2E1 activity was found in uninfected
MDM, it was increased by EtOH (1.8 fold, p < 0.001).
However, levels of CYP2E1 activity were significantly
lower in HIV-1-infected MDM (25–50%), and were en-
hanced with EtOH treatment (2-fold) (Fig. 6A). HIV-1
infection resulted in 30% diminution of CYP2E1 content
detected by Western blot assays in MDM (Fig. 6B).
EtOH treatment up-regulated CYP2E1 content in both
uninfected (3.3-fold) and infected MDM (2.6-fold) as
compared to replicate untreated controls. These changes
were comparable with alterations in functional activity
(Fig. 6A). Treatment with IFN-c did not change
CYP2E1 expression in infected or uninfected cells (data
not shown).
Since it is known that CYP2E1 activity is associated
with oxygen radical production [38], we tested genera-
tion of ROS in MDM after EtOH exposure by DCF
fluorescence assay. EtOH exposure significantly in-
creased ROS (10–23% increase in fluorescence inten-
sity, p < 0.001) and this effect was less prominent in
HIV-1-infected MDM (8–10%), proportional to de-
creased activity of CYP2E1 (p < 0.001) (Fig. 6C). These
data were substantiated by Western blot detection of
215kDa nitrated protein, an established marker of per-
oxynitrite oxidation [39]. As positive controls we used
three nitrated proteins of molecular weight 16kDa (ni-
trated bovine superoxide dismutase), 66kDa (nitrated
bovine serum albumin) and 215kDa (nitrated rabbit
muscle myosin). The level of 215kDa nitrated protein
was significantly lower in HIV-1-infected MDM as
compared to uninfected cells (36%, p < 0.001, Fig.
6D). EtOH treatment caused a 23% increase in nitroty-
rosine content in uninfected MDM (p < 0.01) but it
had no effect on its level in HIV-1-infected MDM
(Fig. 6D). The expression levels of two nitrated pro-
teins with lower molecular weight were very low in
MDM.
Fig. 6. Effects of HIV-1 infection, IFN-c and EtOH on CYP2E1 activity and content, ROS and their modulation by an antioxidant: (A) CYP2E1
activity (nmol/mg protein) in uninfected or HIV-1 infected MDM (9 day post-infection) after 48h EtOH treatment (25mM). (B) CYP2E1 content
determined by Western blots using polyclonal anti-human CYP2E1. Data are expressed as ratio of denstitometric units for intensity of CYP2E1 to a-
actin. (C) DCF fluorescence was measured in identical MDM donors as specific mean fluorescence intensity per milligram protein. (D) Western blots
analyses determined 215kDa nitrated protein immunoreactive species. Relative intensity was expressed as the ratio of nitrated protein to that of a-
actin band intensity. (E) Chymotrypsin-like activity (LLVY) was assayed in MDM treated with 25mM EtOH or IFN-c (10ng/ml) for 48h followed
by 1h incubation with 100lM uric acid. Data were statistically analyzed using two-way ANOVA with Newman–Keuls post-test. Representative data
from four experiments with four independent MDM donors are shown.
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Next, we determined whether ROS generated
through CYP2E1 EtOH metabolism may lead to IPR
dysfunction in MDM. In order to test this premise, we
used a mild anti-oxidant, 100lM uric acid. Its applica-
tion did not change PR activity in MDM, but it was able
to restore chymotrypsin-like activity induced by IFN-c
and down regulated by EtOH to control levels (Fig.
6E). These results indicate that MDM exposure to
EtOH increased CYP2E1 activity and expression, and
EtOH metabolism by CYP2E1 led to ROS generation.
ROS inhibited IPR activity in MDM. HIV-1 infected
MDM demonstrated decreased activity/expression of
CYP2E1 and less ROS production after EtOH
treatment.
4. Discussion
This work sought to analyze the effects of EtOH and
HIV-1 infection on PR function and on expression of
PR/IPR in MDM. EtOH metabolism by CYP2E1 leads
to ROS generation and may be responsible for IPR
impairment in MDM. IPR seems to be susceptible to
ROS generated via ethanol metabolism, because EtOH
prevented IFN-c-stimulated effects on PR activity and
IPR content in MDM. Anti-oxidant reversed the effect
of EtOH on IPR. HIV-1 infection decreased PR activity
and PR/IPR content as well as CYP2E1 activity and
expression. EtOH diminished viral replication attenuat-
ing inhibitory effect of HIV-1 on PR activity. CYP2E1
activity was decreased in HIV-1-infected cells resulting
in less efficient EtOH metabolism by virus-infected cells
and the absence of significant alterations in IPR activity
already down regulated by viral infection (Fig. 7).
Similar to the findings reported for PR expression
during maturation of dendritic cells [40], we found a sig-
nificant increase in chymotrypsin-like activity during
MDM differentiation (from days 3 to 9 in culture). In
dendritic cells, this increase in PR activity was associ-
ated with a synthetic switch from constitutive PR to
IPR [40]. Importantly, we found that differentiated
MDM expressed high levels of IPR even without IFN-
c stimulation. Chymotrypsin-like activity decline in
HIV-1 infected MDM was directly proportional to the
level of virus replication. Decrease of PR activity in
HIV-1-infected MDM was accompanied by diminished
expression of PR and IPR as compared to uninfected
MDM. This HIV-1 related decline in activity and
expression may be associated with Tat-induced (tran-
scriptional transactivator of HIV-1) PR malfunction
[41,42].
Immune response against viral or bacterial infection
activates the PR regulator PA28 a/b, thereby substitut-
ing constitutive subunits of PR with IPR subunits
(LMP2, LMP7, and MELC-1) [21]. Indeed, IFN-c up-
regulated PR activity in MDM and HIV-1-infected
MDM; however, PR activity was lower in infected cells
even after IFN-c treatment as compared to MDM.
While IFN-c had no effect on PR level, it increased
LMP2/LMP7 expression in MDM indicating that major
increase in PR activity after IFN-c stimulation is associ-
ated with IPR. Similar to catalytic activity, IPR expres-
sion was lower in HIV-1 infected and IFN-c stimulated
MDM when compared to IFN-c-treated uninfected
MDM. Since HIV-1 alters catalytic activities of PR
and expression of PR/IPR, these changes may interfere
with processing of MHC class I antigens resulting in im-
paired antigen presentation. Thus, viral replication may
negatively regulate elimination of infected cells by cyto-
toxic T lymphocytes.
Next, we examined the effects of EtOH on PR func-
tion and PR/IPR expression in MDM. EtOH treatment
did not affect the activity or expression of PR in unin-
fected MDM, but it attenuated both IFN-c-induced
PR activity (predominantly associated with IPR) and
enhanced LMP2/LMP7 expression in MDM. Currently,
EtOH-induced inhibition of PR activity was demon-
strated only in liver tissue derived from EtOH-fed rats
and mice [29,43] and in hepatoma cell lines treated with
EtOH (HepG2) [44]. In vivo studies suggest more prom-
inent impairment of 26S rather than 20S PR with EtOH
treatment. While dysfunction of 26S PR leads to ineffi-
cient degradation of short-lived abnormal proteins by
the ubiquitin-PR pathway, EtOH-induced impairment
of IPR in MDM found in this study may potentially re-
sult in impaired antigen presentation. In uninfected
cells, EtOH not only diminished PR activity, but also
Fig. 7. Schematic representation of possible mechanistic pathway
derived from the present findings. EtOH induces CYP2E1 activity in
uninfected MDM, which in turn metabolizes EtOH, leading to
generation of ROS and subsequent decrease in IRP expression and
function (shown on left flow chart). Infection of MDM with HIV-1
down regulates PR function and expression of PR/IPR (shown on
right flow chart). Both EtOH and HIV-1 impair IPR in MDM and
may result in inefficient antigen presentation.
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decreased the levels of LMP2 and LMP7 content in-
duced by IFN-c stimulation. It was shown that LMP2
and LMP7 deficient mice had reduced CD8+T lympho-
cyte numbers and impaired antigen presentation [45,46].
EtOH-elicited IPR impairment observed for the first
time in APC could underlie immunosuppressive effects
of alcohol abuse [47].
Ethanol even at a low concentration protected the PR
catalytic activity in HIV-1-infected MDM, possibly
through suppression of virus replication. This protective
effect of EtOH was not seen in the expression of 20S/19S
or LMP2/LMP7 in infected MDM after EtOH treat-
ment as compared as compared to HIV-1-infected
MDM without EtOH exposure. However, it is not clear
if this protection is an in vitro phenomenon, or if it ex-
ists in vivo in HIV patients with alcoholics.
Contrary to results seen in uninfected MDM, EtOH
did not decrease PR activity up-regulated by IFN-c
stimulation in HIV-1-infected MDM. This might be re-
lated to differences in EtOH metabolism in HIV-1-in-
fected versus uninfected MDM. Thus, we examined
activity and expression of CYP2E1 for EtOH metabo-
lism in MDM. EtOH treatment resulted in increased
CYP2E1 activity and expression in MDM, whereas
HIV-1 infection reduced CYP2E1 activity and expres-
sion. Although CYP2E1 expression was demonstrated
before in macrophages [26,48], this is the first report
analyzing effects of EtOH and HIV-1 on CYP2E1 activ-
ity and expression in human MDM. The CYP2E1-med-
iated EtOH metabolism pathway leads to production of
ROS [49] and superoxide anions in human macrophages
[50]. Indeed, we detected higher levels of ROS in EtOH
treated MDM, but found only a modest increase in
HIV-1 MDM. These results closely paralleled activity
and expression of CYP2E1. Detection of significantly
higher levels of nitrotyrosine in uninfected EtOH treated
MDM as compared to infected MDM under identical
conditions further substantiated our observations. The
absence of a significant increase of ROS after EtOH
treatment in HIV-1 infected MDM may explain why
IPR activity was not altered in infected cells after alco-
hol exposure. It was shown that IPR are more suscepti-
ble to ROS-mediated inhibition compared with
constitutive PR [39]. Indeed, we were able to completely
restore the IPR activity in EtOH-treated and IFN-c
stimulated MDM by anti-oxidant.
In summary, the present study demonstrates that
HIV-1 infection modulates function and expression of
PR and IPR in APC. We found significant induction
of CYP2E1 by EtOH treatment of uninfected MDM
resulting in the enhanced production of ROS and de-
crease in IRP expression and function. IPR dysfunction
could partially underlie immunosuppression observed in
alcoholics or HIV-1-infected patients leading to defec-
tive antigenic peptide processing. Furthermore, our re-
sults indicate beneficial effects of anti-oxidants.
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